TNF
AbbVie highlights treatment adherence
June 12, 2014Sales and Marketing ALIGN, AbbVie, Abbott, Crohn’s disease, TNF, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, treatment, ulcerative colitis
Patients with inflammatory diseases tend to be better at following their treatment regimes with TNF inhibitors rather than other medicines, …
Abbott buys into Galapagos’ RA candidate
February 29, 2012Research and Development, Sales and Marketing Abbott, Galapagos, Humira, JAK, RA, TNF
Abbott has struck a deal with Galapagos to develop and commercialise a promising oral JAK1 inhibitor to treat multiple autoimmune …
Price concession helps change NICE’s mind on Simponi
May 13, 2011Sales and Marketing NICE, Simponi, TNF, merck sharp and dohme
NICE has provisionally recommended Merck Sharp & Dohme’s Simponi for rheumatoid arthritis alongside other drugs in the TNF inhibitor class. …
Abbott wins $1.7bn Humira case
February 24, 2011Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis
Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …
NICE re-thinks arthritis guidance
June 25, 2010Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis
NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …
Ulcerative colitis market set to double by 2018
February 12, 2010Sales and Marketing Humira, Simponi, TNF, ulcerative colitis
The market for ulcerative colitis drugs is set to double over the ten years to 2018 when it will hit …
Simponi approved in Europe
October 8, 2009Sales and Marketing RA, Simponi, TNF
Rheumatic disease drug Simponi has received marketing approval for Europe, where it will be marketed by Schering-Plough.The drug is indicated …
TNF blockers must carry children’s cancer warning
August 7, 2009Research and Development, Sales and Marketing FDA, RA, TNF
The FDA has ruled that TNF blocker drugs should carry new warnings of the increased risk of certain cancers for …
Remicade loses out in ankylosing spondylitis
November 15, 2007Sales and Marketing TNF
NICE has rejected Schering-Plough's Remicade as a treatment for the debilitating form of spinal inflammation known as ankylosing spondylitis.The Institute …
